Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Suzhou Transcenta Therapeutics Co., Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 3 examiners and 3 art units, so the portfolio does not present a single examination channel.
STOICA, ELLY GERALD is the busiest examiner, with 1 pending matter. Counsel should coordinate claim strategy across the separate examiner and art-unit assignments while tailoring each response to its individual record.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
| BALLARD, KIMBERLY | 1 | 53.6% | +49.5% |
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575326 | NOVEL ANTI-MASP-2 ANTIBODIES | STOICA, ELLY GERALD | — |
| 18555341 | NOVEL ANTI-HVEGFR2 ANTIBODIES | BALLARD, KIMBERLY | — |
| 18549928 | METHOD OF TREATING DISEASES USING GREMLIN1 ANTAGONISTS | BELYAVSKYI, MICHAIL A | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1675 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575326 | NOVEL ANTI-MASP-2 ANTIBODIES | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Dec 29, 2023 |
| 18555341 | NOVEL ANTI-HVEGFR2 ANTIBODIES | BALLARD, KIMBERLY | 1675 | §112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18549928 | METHOD OF TREATING DISEASES USING GREMLIN1 ANTAGONISTS | BELYAVSKYI, MICHAIL A | 1644 | §103DP | Final Rejection | — | Pending | Sep 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuzhou Transcenta Therapeutics Co., Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Elly Gerald Stoica has the most, with 1 of Suzhou Transcenta Therapeutics Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
